"The transaction to be executed through Luye Pharma's subsidiary...

"The transaction to be executed through Luye Pharma's subsidiary A-Bio Pharma values Prime Biologics at S$60 million."

"The LOI provides for a potential investment of up to S$20m by a significant Asian Life Sciences fund."

Seems this time $20m for 30% of Prime Biologics is fair, considering the previous deal. NSP will free carried 60%, once $20m investment done, NSP can easily sell another 10% for $6m cash.

quote:

Singapore: SGX-listed Luye Pharma Group is investing S$6 million (A$4.6 million) in NuSep's Singapore subsidiary Prime Biologics in exchange for a 10 percent interest in the company. Under the terms of the deal, NuSep will issue Luye with 6 million shares in Prime Biologics giving it a 10 percent shareholding. NuSep currently holds the remaining 90 percent, but expects to sell this and bring its holding down to 50 percent as additional investors subscribe for shares in Prime Biologics. The transaction to be executed through Luye Pharma's subsidiary A-Bio Pharma values Prime Biologics at S$60 million and is the first such investment by a pharma company in NuSep's "PrIME" technology. The deal will enable NuSep to establish a physical presence for Prime Biologics in Singapore. - See more at: http://www.biospectrumasia.com/biospectrum/news/3084/luye-pharma-invests-nuseps-prime-technology#.UbxyATtG18Q